Erius, 5 mg 10 pcs

Pharmacological group:

Anti-allergic agent – H1-histamine receptor blocker.

Pharmacological action:

Erius is a long-acting antihistamine drug, a blocker of peripheral histamine H1-receptors. Desloratadine is the primary active metabolite of loratadine.

Inhibits the cascade of allergic inflammatory reactions, including Release of proinflammatory cytokines, including interleukins IL-4, IL-6, IL-8, IL-13, release of proinflammatory chemokines, production of superoxide anions by activated polymorphonuclear neutrophils, adhesion and chemotaxis of eosinophils, release of adhesion molecules, such as P-selectin, IgE – mediated release of histamine, prostaglandin D2 and leukotriene C4.

Thereby it prevents and facilitates the development of allergic reactions, has antipruritic and antiexudative properties, reduces capillary permeability and prevents development of tissue edema and smooth muscle spasm.

The drug has no effect on the CNS, practically has no sedative effect (does not cause drowsiness) and does not affect the speed of psychomotor reactions. It does not cause prolongation of the QT interval on the ECG.

The effects of Erius begin within 30 minutes after oral administration and last for 24 hours.

Indications

– Seasonal (pollinosis) and year-round allergic rhinitis (elimination or relief of sneezing, nasal congestion, nasal mucus discharge, nasal itching, palate itching, itchy and red eyes, lacrimation).

– Chronic idiopathic urticaria (reduction or elimination of skin itching, rash).

Active ingredient

Composition

The Erius tablets are blue coated, round, biconvex, with the Schering-Plough trademark in the form of stylized letters “SP” on one side.

1 tablet contains:

Active ingredient:

desloratadine 5 mg.

Associates:

Calcium hydrophosphate dihydrate,

Cellulose microcrystalline,

Corn starch,

Talc.

Coating composition:carnauba wax, white wax, film coating blue and transparent (lactose monohydrate, hypromellose, titanium dioxide, macrogol, aluminum blue varnish FD&C №2 (indigo carmine, E132).

How to take, the dosage

Adults and adolescents aged 12 years and older are prescribed 5 mg once daily, regardless of meals, preferably at the same time of day.

The tablet should be swallowed whole, without chewing, with a small amount of water.

Interaction

Eriuc does not increase the effect of ethanol on the CNS.

Eating has no effect on the effectiveness of the drug.

Special Instructions

The efficacy and safety of Erius in syrup form in children under 1 year of age has not been established. In most cases, rhinitis in children under 2 years of age has an infectious nature.

The efficacy of Erius in rhinitis of infectious etiology has not been studied.

The differential diagnosis between allergic rhinitis and rhinitis of other origin in children less than 2 years of age is difficult.

In making the differential diagnosis, attention should be paid to the presence or absence of foci of infection or upper respiratory tract structural abnormalities, a thorough history, examination, and appropriate laboratory tests and skin tests.

In the recommended dose, Erius does not affect driving or operating machinery.

Synopsis

Contraindications

– hypersensitivity to the components of the drug;

– pregnancy;

– lactation (breastfeeding);

– age less than 12 years;

– hereditary diseases (fructose intolerance, glucose/galactose malabsorption or insufficiency of sucrose/isomaltase in the body) due to the presence of sucrose and sorbitol in the syrup.

With caution:The drug should be used in severe renal failure.

Side effects

Additional fatigue (1.2%), dry mouth (0.8%), headache (0.6%) have been reported while using the drug.

Cardiovascular system:very rarely, tachycardia, palpitations.

Digestive system disorders:very rarely – increased liver enzyme activity, increased bilirubin concentration.

Allergic reactions:very rare – anaphylaxis, rash.

Overdose

Symptoms: At a dose greater than 5 times the recommended dose did not result in any symptoms. In clinical trials, daily use in adults and adolescents of desloratadine at doses up to 20 mg for 14 days was not accompanied by statistically or clinically significant cardiovascular changes.

In a clinical and pharmacological study, use of desloratadine at a dose of 45 mg/day (9 times the recommended dose) for 10 days did not cause QT interval prolongation and was not accompanied by any serious side effects.

Treatment: In case of accidental ingestion of large amounts of the drug – gastric lavage, administration of activated charcoal; if necessary – symptomatic therapy.

Desloratadine is not excreted by hemodialysis, the effectiveness of peritoneal dialysis has not been established.

Pregnancy use

The use of the drug during pregnancy is not recommended due to the lack of clinical data on the safety of its use during this period.

Desloratadine is excreted with breast milk, so the use of Erius during breastfeeding is not recommended.

Similarities